Detalhe da pesquisa
1.
Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study.
Gastroenterology
; 165(4): 963-975.e5, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37499955
2.
Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab.
Clin Gastroenterol Hepatol
; 21(11): 2908-2917.e10, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36280102
3.
Patients With Inflammatory Bowel Diseases and Higher Visceral Adipose Tissue Burden May Benefit From Higher Infliximab Concentrations to Achieve Remission.
Am J Gastroenterol
; 118(11): 2005-2013, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37207314
4.
Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases.
Dig Dis Sci
; 64(12): 3674-3675, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31642007
5.
Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases.
Dig Dis Sci
; 64(6): 1651-1659, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30835029
6.
Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease.
BMJ Open Gastroenterol
; 8(1)2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34764142
7.
Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease.
J Crohns Colitis
; 13(8): 963-969, 2019 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31087100